Supplementary Figure 1. Indexes at the start and after 3 months of nilotinib therapy.

(A) **HOMA2-IR index** [reflecting hepatic insulin resistance]; (B) **Insulin sensitivity index** (HOMA2-%S) derived from the HOMA2 calculation as percentages of a normal reference population; (C) **ISI_{0,120} or Gutt index** [tends to reflect peripheral insulin resistance and correlates with euglycemic clamp]; (D) Steady state **β-cell function** (HOMA2-%B) derived from HOMA2 as percentages of a normal reference population.

**Supplementary Figure 2.** Change in β-cell function based on the HOMA2-%B difference (HOMA2-%B_{3\text{month}} – HOMA2-%B_{\text{start}}) at the start and the 3rd month of nilotinib therapy in 2 patients who fulfilled criteria of diabetes mellitus (DM) during nilotinib treatment compare to the 8 other patients.
Supplementary Figure 1.

A. **p = 0.008**

B. **p = 0.006**

C. **p = 0.002**

D. **p = 0.922**
Supplementary Figure 2.

\[ p = 0.024 \]